Eli Lilly and Company (NYSE:LLY) Shares Sold by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,084 shares of the company’s stock after selling 248 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Eli Lilly and Company were worth $2,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new position in Eli Lilly and Company during the third quarter worth about $27,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at about $36,000. Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Performance

LLY traded up $31.71 during trading on Monday, hitting $766.68. The stock had a trading volume of 3,387,277 shares, compared to its average volume of 3,090,747. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The firm has a market capitalization of $728.66 billion, a P/E ratio of 112.91, a PEG ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company’s 50-day moving average price is $761.06 and its 200 day moving average price is $672.28.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the company posted $1.62 earnings per share. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.